ModifiedUnitedHealthcarePolicy N/A

Provider Administered Drugs — Site of Care (Pennsylvania only)

Policy governing when hospital outpatient facility infusion services are medically necessary for specified provider-administered specialty drugs and IVIG/SCIG in Pennsylvania; affects providers submitting claims for these medications and site-of-care determinations.

Policy Summary

PayerUnitedHealthcare

PolicyProvider Administered Drugs — Site of Care (Pennsylvania only)

Policy CodePolicy N/A

Change TypeMaterial revisions to documentation, instability criteria, and initial/re-initiation rules

Effective DateMay 1, 2025

Next Review DateN/A

Key ActionSubmit medical records demonstrating the individual meets at least one listed medical necessity criterion when requesting hospital outpatient facility infusion authorization.

SourceLink

POLICY UPDATE CHANGES

Replaced language about requiring submission of medical records to indicate outpatient hospital facility-based administration is medically necessary with clarified wording that submission of medical records documenting medical necessity is required.

Added criterion requiring that the patient is medically unstable and at risk of requiring services/equipment available only in an outpatient hospital setting (examples provided).

Removed criterion that broadly required documentation that an individual is medically unstable for administration at alternative sites determined by complex medical status or therapy

Refined language about prior severe infusion reactions to specify prior episodes (not including first or second infusion) unresponsive to standard measures as a trigger for higher level care.

Added HCPCS codes J1552 and J1628 to Applicable Codes and revised description for Q5133; added Tremfya (guselkumab) to list of medications requiring healthcare provider administration.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Hospital Outpatient Facility Infusion — Coverage Criteria

Criteria for outpatient hospital facility-based infusion

Covered when ANY of the following criteria are met and documented in medical records:

Medically unstable requiring hospital‑only services/equipment: The patient is medically unstable and at risk of requiring medical services and equipment available only in an outpatient hospital setting.

Examples: need for endotracheal tube, chest (thoracic) insertion equipment, cricothyroidotomy set, mechanical ventilator.

History of cardiopulmonary conditions increasing infusion risk: History of cardiopulmonary conditions that cause an increased risk of severe adverse reactions during or immediately following infusion.

Triggers need for outpatient hospital setting.

Inability to tolerate fluid volume load: An inability to tolerate fluid volume load (for intravenous infusions only) despite using the minimum amount of fluid required for infusion (e.g., unstable renal function).

Requires hospital‑level monitoring/equipment.

Severe vascular access issues: Severe patent vascular access issues (for intravenous infusions only) that require specialized equipment only available in an outpatient hospital setting (e.g., ultrasound guidance) and member is not a viable candidate for long‑term vascular access devices such as PICC line or port‑a‑cath.

May justify outpatient hospital infusion.

Prior severe/prolonged adverse events to requested therapy: Previous episode(s) of severe or potentially life‑threatening adverse events (e.g., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure), not including the first or second infusion, that occurred while receiving requested therapy and were unresponsive to acetaminophen, steroids, diphenhydramine, fluids, infusion rate reductions, or other pre‑medications.

Indicates higher‑level care required.

Initial or re‑initiation infusions: Initial infusion or re‑initiation of previous therapy after more than 6 months (excludes drugs dosed at an interval of 6 months or greater) for a short duration (e.g., 4 weeks).

May require facility‑based administration per guidelines.

Homecare/provider assessment: The homecare or home infusion provider has deemed that the individual or home environment is not suitable for home infusion therapy.

Supports facility‑based administration when no ambulatory options exist.

When criteria for hospital outpatient facility infusion are not met, the policy directs use of alternative sites of care. Acceptable alternatives include non‑hospital outpatient infusion settings, physician office administration, ambulatory infusion suites, or home infusion services. These alternative sites of care are recognized as well‑accepted places of service for medication infusion therapy and should be used when the member does not meet any hospital outpatient facility medical necessity criteria.

The policy removed a previously broad, general requirement that an individual be “medically unstable for administration at alternative Sites of Care” and replaced it with more specific instability criteria. The revision defines discrete examples of instability (for example, risk of requiring services/equipment available only in an outpatient hospital setting) and other narrowly described clinical situations rather than relying on a single, catch‑all ‘‘medically unstable’’ statement.

Per AAAAI guidance and the policy, individuals who have previously tolerated IGIV therapy without a history of infusion‑related adverse events may be considered for lower levels of supervision (for example, home or office administration) rather than hospital outpatient facility‑based infusion, provided the clinical record documents safe suitability for the lower‑intensity site of care.

Initial and Re-initiation Infusion Rules

Initial/Re-initiation therapy

Initial infusion or re‑initiation rules

Initial/re‑initiation: Initial infusion or re‑initiation of previous therapy after more than 6 months (excluding drugs dosed at intervals of 6 months or greater) may justify temporary hospital outpatient facility‑based administration for a short duration (e.g., 4 weeks).

Initial infusion

Initial infusion — specific initial infusion rules

Initial infusion requirement: All initial infusions of IGIV should be administered under physician supervision in a facility equipped to manage the most severe acute medical complications.

Per AAAAI guidance referenced in policy history and supporting information.

Applicable Procedure and Drug Codes

Procedure CPT/HCPCS Codes (Immune Globulin)CPT

90283	Immune globulin (IGIV), human; for intravenous use.
90284	Immune globulin (SCIG) , human, for use in subcutaneous infusions, 100 mg, each

Applicable J-codes, unclassified codes, and biosimilar Q-codesHCPCS

C9399	Unclassified drugs or biologicals.
J0129	Injection, abatacept; 10 mg
J0180	Injection, agalsidase beta, mg
J0217	Injection, velmanase alfa-tycv , 1 mg
J0218	Injection, olipudase alfa-rpcp, 1 mg
J0219	Injection, avalglucosidase alfa-ngpt; 4 mg
J0221	Injection, alglucosidase alfa, (Lumizyme); 10 mg
J1203	Injection, cipaglucosidase alfa-atga, 5 mg
J1322	Injection, elosulfase alfa, 1 mg
J1426	Injection, casimersen, 10 mg

1–10 of 45

1/5

Applicable HCPCS Codes (added/revised)HCPCS

J1552	HCPCS code added to Applicable Codes
J1628	HCPCS code added to Applicable Codes
Q5133	Revised description for HCPCS code Q5133

Ongoing facility infusion reassessment interval — inv-09

Maximum approval durationOngoing outpatient hospital facility-based infusion approvals limited to no more than 6 months before reassessment.

Reassessment ruleIf more than one criterion is met, the greatest applicable approval time period will be allowed; otherwise reassess at 6 months.

Purpose of reassessmentAllows evaluation of ability to transition to an alternative site of care (home, ambulatory infusion suite, or physician office).

Prior Authorization, Documentation, and Site-of-Care Actions

Prior Authorization

Prior Authorization Required

Prior authorization / case review is required. Submit medical records demonstrating the individual meets at least one of the listed criteria for outpatient hospital facility-based administration.

Prior authorization required when medical records document at least one listed criterion
Approval duration: greatest of applicable time periods when multiple criteria met

Documentation Required

Documentation Required for Medical Necessity

Submission of medical records is required to support that outpatient hospital facility-based administration is medically necessary. Requests without the required documentation may be delayed or denied.

Include clinical notes, infusion records, relevant diagnostic testing, and documentation of prior adverse events or stability concerns
Failure to submit required records may lead to denial or delay of authorization

Site-of-Care Selection Guidance

Prior Authorization

Hospital outpatient allowed only when a listed medical necessity criterion is met

Hospital outpatient facility administration is covered only when the patient meets at least one medical necessity criterion in the policy; if none are met, alternate sites of care are preferred.

Criteria include cardiopulmonary risk, medical instability requiring hospital‑only equipment, inability to tolerate IV fluid load, severe vascular access issues, prior severe adverse events unresponsive to standard measures, initial/re‑initiation infusions, IgA deficiency with anti‑IgA (IVIG/SCIG), unsuitable home environment with no ambulatory options, and prescriber inability to give in office.

Note

Follow AAAAI guidance; home infusions appropriate for selected patients

Site‑of‑care selection should follow AAAAI guidance and this policy’s criteria; home infusions and other lower‑acuity settings are appropriate for selected patients, but specified clinical conditions necessitate hospital outpatient facility administration and must be documented.

AAAAI recommends all initial IGIV infusions be administered under physician supervision in a facility equipped to manage severe acute complications.
Individuals who have tolerated IGIV without adverse events may be considered for lower levels of supervision (eg, home or office).

Step Therapy and External Tool Usage

Requirement	Preferred alternative site(s)
If an individual does not meet criteria for outpatient hospital facility infusion	Non-hospital outpatient infusion, physician office, ambulatory infusion suite, or home infusion services
Alternative sites of care are well-accepted places of service for medication infusion therapy	As clinically appropriate and available, use the least intensive suitable site (non-hospital outpatient, office, ambulatory infusion, home)

Policy statement	Implication for coverage management
UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in administering health benefits	These tools could impose step therapy or sequencing pathways that affect coverage determinations
When third-party criteria are used, they supplement but do not replace federal, state, or contractual benefit requirements	Prior authorization and coverage decisions may follow external criteria where applicable; providers should be aware that utilization management pathways may be applied

Key Definitions

Immune Globulin (IG/IgG) definition — inv-19

DefinitionImmune Globulin (IG/IgG) refers to IgG products used for replacement therapy; terminology includes Immune Globulin, immunoglobulin, gamma globulin, IVIG (intravenous) and SCIG (subcutaneous).

Routes of administrationIntravenous Immune Globulin (IVIG/IGIV) and Subcutaneous Immune Globulin (SCIG/IGSC).

Clinical useUsed for IgG replacement therapy in immunodeficiency diseases or other indications where IgG replacement is clinically indicated.

Site of Care definition — inv-20

DefinitionSite of Care denotes the physical location where infusion is administered: hospital inpatient, hospital outpatient, physician office, ambulatory infusion suite, or home-based setting.

Hospital outpatient vs alternatives

Clinical Background

Immunoglobulin G replacement therapy (IVIG or SCIG) is used to treat patients with primary or secondary immunodeficiency disorders characterized by low IgG levels or impaired IgG function. IVIG is typically administered intravenously on an intermittent schedule (commonly monthly), while SCIG is given subcutaneously on a more frequent schedule (weekly or biweekly). Site‑of‑care decisions should follow clinical guidance (for example, AAAAI recommendations) and be based on the patient’s clinical condition; options include hospital outpatient or inpatient supervision, physician office administration, ambulatory infusion suites, and home‑based infusion with or without nurse supervision. The policy recognizes that home and ambulatory settings are appropriate for selected patients and that certain clinical scenarios (eg, initial infusions, specific comorbidities, or risk of severe acute complications) warrant facility‑level supervision.

Policy Summary

PayerUnitedHealthcare

PolicyProvider Administered Drugs — Site of Care (Pennsylvania only)

Policy CodePolicy N/A

Change TypeMaterial revisions to documentation, instability criteria, and initial/re-initiation rules

Effective DateMay 1, 2025

Next Review DateN/A

Key ActionSubmit medical records demonstrating the individual meets at least one listed medical necessity criterion when requesting hospital outpatient facility infusion authorization.

SourceLink

On This Page

Documentation Required

Documentation-Based Medical Necessity Required

Documentation must show that the individual meets at least one of the specified clinical criteria (e.g., history of cardiopulmonary conditions increasing risk, medically unstable and at risk of requiring services/equipment available only in an outpatient hospital setting, inability to tolerate fluid volume load, severe vascular access issues, treatment at alternative site presents health risk, documented severe adverse events not responsive to standard interventions, initial or re-initiation infusions, specific IG deficiency criteria for IVIG/SCIG, or home environment not suitable and no ambulatory infusion options).

Medical records must clearly map to one or more listed criteria
If more than one criterion is met, the longest applicable approval period applies
Ongoing outpatient hospital facility-based infusion generally limited to 6 months for reassessment (unless other criterion-specific durations apply)

Note

Site-of-Care Preference and External Criteria Tools

If criteria for outpatient hospital facility infusion are not met, alternative sites of care (non-hospital outpatient infusion center, physician office, ambulatory infusion suite, or home infusion) are preferred. UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in benefit administration.

Preferred place of service codes: 19 Off Campus-Outpatient Hospital; 22 On Campus-Outpatient Hospital (use only when criteria met)
Alternative sites of care should be used when facility criteria are not satisfied
UnitedHealthcare reserves the right to apply federal/state/contractual coverage requirements and to use third-party criteria tools

High-level supervision — inv-21

High-level supervision situationsPrior serious infusion reaction (eg, anaphylaxis, seizure, myocardial infarction, renal failure) that may require facility-level interventions.

Therapy-naive or initial infusionsAll initial infusions of IVIG and changes in IGIV products should be administered under physician supervision in a facility equipped to manage severe acute complications.

Continued moderate/serious infusion reactions or physical/cognitive impairmentIndividuals with ongoing moderate or serious infusion-related adverse reactions or significant physical/cognitive impairment necessitating higher-level monitoring and intervention.